Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

217
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
217
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

1.4K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
1.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

739
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
739
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

270
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
270
Drug Clearance: Overview01:06

Drug Clearance: Overview

130
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
130

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic variants of p21 and p27 and hepatocellular cancer risk in a Chinese Han population: a case-control study.

International journal of cancer·2012
Same author

Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects.

Stem cells (Dayton, Ohio)·2012
Same author

MAIGO2 is involved in abscisic acid-mediated response to abiotic stresses and Golgi-to-ER retrograde transport.

Physiologia plantarum·2012
Same author

The internal dynamics of mini c TAR DNA probed by electron paramagnetic resonance of nitroxide spin-labels at the lower stem, the loop, and the bulge.

Biochemistry·2012
Same author

Electrochemical depassivation of zero-valent iron for trichloroethene reduction.

Journal of hazardous materials·2012
Same author

Derivation of quantum work equalities using a quantum Feynman-Kac formula.

Physical review. E, Statistical, nonlinear, and soft matter physics·2012

Related Experiment Video

Updated: Aug 12, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.5K

Roxadustat: Do we know all the answers?

Qiu-Yu Li1, Qian-Wen Xiong2, Xuefeng Yao3

  • 1Department of Nephrology, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China.

Biomolecules & Biomedicine
|February 1, 2023
PubMed
Summary
This summary is machine-generated.

Roxadustat treats anemia in chronic kidney disease (CKD) but may cause adverse effects. Further long-term studies are needed to assess its safety and potential risks beyond the kidneys.

More Related Videos

Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

277
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.0K

Related Experiment Videos

Last Updated: Aug 12, 2025

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.5K
Comprehensive Analysis of Drug Response using the FLICK Assay
09:42

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

277
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.0K

Area of Science:

  • Nephrology
  • Pharmacology
  • Hematology

Background:

  • Anemia is a frequent complication of chronic kidney disease (CKD), worsening with disease progression.
  • Erythropoiesis-stimulating agents (ESAs) are standard treatment, but resistance and safety concerns drive research into alternatives.
  • Iron deficiency and reduced erythropoietin (EPO) production are primary causes of CKD-related anemia.

Purpose of the Study:

  • To review the clinical evidence on the safety and potential adverse effects of roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).
  • To discuss the impact of roxadustat on organ systems beyond the kidneys.
  • To highlight the need for long-term follow-up for broader regulatory approval.

Main Methods:

  • Review of clinical trial data and existing literature on roxadustat.
  • Analysis of reported adverse events associated with roxadustat treatment.
  • Evaluation of roxadustat's biological effects on non-renal systems.

Main Results:

  • Roxadustat, an oral HIF-PHI, is approved for CKD-related anemia in several regions.
  • Clinical trials indicate adverse effects including cardiovascular disease, hyperkalemia, and infections.
  • Concerns exist regarding roxadustat's potential effects on other organs and systems.

Conclusions:

  • Roxadustat offers an alternative oral therapy for anemia in CKD patients.
  • Potential detrimental effects on non-renal systems warrant careful consideration.
  • Long-term safety data and follow-up are crucial for future global approval and patient management.